ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
131.065,44
-1,55%
S&P 500
5.702,55
-0,19%
US Dollar vs BRL
5,5151
0,00%
Bitcoin
63.031,90
-0,54%
Brent Oil
74,135
0,00%
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Kintara Therapeutics Inc (KTRA)

  7. Kintara Therapeutics Inc (KTRA) Notícias

KTRA

Kintara Therapeutics (KTRA)

Kintara Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:KTRA
DataHoraFonteTítuloCódigoCompanhia
20/09/202417:20Edgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:KTRAKintara Therapeutics Inc
20/09/202417:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KTRAKintara Therapeutics Inc
20/09/202410:25PR Newswire (US)Kintara Therapeutics Announces Adjournment of Special Meeting of Stockholders until October 4, 2024NASDAQ:KTRAKintara Therapeutics Inc
18/09/202409:30PR Newswire (US)Kintara Therapeutics Reminds Stockholders to Vote by Thursday to Allow for Completion of the Proposed Merger with TuHURA BiosciencesNASDAQ:KTRAKintara Therapeutics Inc
11/09/202409:30PR Newswire (US)Kintara Therapeutics Provides Update on Corporate Developments and REM-001 Clinical StudyNASDAQ:KTRAKintara Therapeutics Inc
09/09/202409:30PR Newswire (US)Kintara Therapeutics to Hold Special Meeting of Stockholders to Allow for Completion of the Proposed Merger with TuHURA Biosciences, Inc.NASDAQ:KTRAKintara Therapeutics Inc
19/08/202410:00PR Newswire (US)TuHURA Biosciences and Kintara Therapeutics Announce Kineta Inc. Reopens Enrollment for VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor CancerNASDAQ:KTRAKintara Therapeutics Inc
14/08/202401:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:KTRAKintara Therapeutics Inc
12/08/202418:01Edgar (US Regulatory)Form S-4/A - Registration of securities, business combinations: [Amend]NASDAQ:KTRAKintara Therapeutics Inc
08/07/202407:30PR Newswire (US)TuHURA Biosciences Enters into Exclusivity and Right of First Offer Agreement for Kineta, Inc.'s KVA12123 Novel anti-VISTA Checkpoint InhibitorNASDAQ:KTRAKintara Therapeutics Inc
01/07/202409:35PR Newswire (US)Kintara Therapeutics and TuHURA Biosciences Provide Update on Recent Corporate and Clinical Advancements and Outline Near Term MilestonesNASDAQ:KTRAKintara Therapeutics Inc
03/06/202409:35PR Newswire (US)TuHURA Biosciences and Kintara Therapeutics Announce Positive Results from Phase 1b Trial of IFx-2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC)NASDAQ:KTRAKintara Therapeutics Inc
17/05/202417:10Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:KTRAKintara Therapeutics Inc
17/05/202417:05Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:KTRAKintara Therapeutics Inc
14/05/202417:45PR Newswire (US)Kintara Therapeutics Announces Fiscal 2024 Third Quarter Financial ResultsNASDAQ:KTRAKintara Therapeutics Inc
14/05/202417:40Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:KTRAKintara Therapeutics Inc
13/05/202417:06Edgar (US Regulatory)Form S-4 - Registration of securities, business combinationsNASDAQ:KTRAKintara Therapeutics Inc
05/04/202414:09PR Newswire (US)Kuehn Law Encourages KTRA, ABIO, SWAV, and NS Investors to Contact Law FirmNASDAQ:KTRAKintara Therapeutics Inc
03/04/202408:00PR Newswire (US)Kintara Therapeutics and TuHURA Biosciences Enter into Definitive Merger AgreementNASDAQ:KTRAKintara Therapeutics Inc
27/03/202410:00PR Newswire (US)Kintara Therapeutics Announces Expansion of REM-001 Clinical Study to Include Patients on PembrolizumabNASDAQ:KTRAKintara Therapeutics Inc
14/02/202418:07PR Newswire (US)Kintara Therapeutics Announces Fiscal 2024 Second Quarter Financial Results and Provides Corporate UpdateNASDAQ:KTRAKintara Therapeutics Inc
12/02/202411:00PR Newswire (US)Kintara Therapeutics Announces Initiation of REM-001 Clinical Trial for the Treatment of Cutaneous Metastatic Breast CancerNASDAQ:KTRAKintara Therapeutics Inc
18/12/202318:05Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:KTRAKintara Therapeutics Inc
07/12/202311:00PR Newswire (US)Kintara Therapeutics Announces Review of Strategic AlternativesNASDAQ:KTRAKintara Therapeutics Inc
05/12/202311:00PR Newswire (US)Kintara Therapeutics Granted Extension by Nasdaq to Regain Compliance with the Stockholders' Equity Continued Listing RequirementNASDAQ:KTRAKintara Therapeutics Inc
13/11/202318:10PR Newswire (US)Kintara Therapeutics Announces Fiscal 2024 First Quarter Financial Results and Provides Corporate UpdateNASDAQ:KTRAKintara Therapeutics Inc
31/10/202309:00PR Newswire (US)Kintara Therapeutics Announces Preliminary Topline Results From GBM AGILE StudyNASDAQ:KTRAKintara Therapeutics Inc
27/10/202317:05Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:KTRAKintara Therapeutics Inc
04/10/202317:35Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:KTRAKintara Therapeutics Inc
21/09/202310:35GlobeNewswire Inc.Dawson James Securities Announces October Date for 8th Annual Small Cap Growth ConferenceNASDAQ:KTRAKintara Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:KTRA

Seu Histórico Recente

GATE
CRPUSDT
CropperFinance
TG
A285HT
Abertis Infraestructuras...
BIT
S32587
Societe Generale Effekten
TG
A3LMPZ
SSE
NASDAQ
FDML
Federal-Mogul Holdings Corp
BIT
P1TAY1
BNP Paribas Issuance
COIN
VGAAUSD
VegaFi
NASDAQ
BLSA
BCLS Acquisition
LSE
FG54
Citi Fun 24
LSE
RIII
Rights & Issues Investment
TSXV
LCP
TG
A3LK2T
BMW Finance NV
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados